Search Results
435 Results Found for “heart failure”
ABLATE versus PACE: Pacemaker strategy reduces clinically relevant events in older patients with persistent atrial fibrillation Randomised trial shows substantially fewer hospitalisations and repeat interventions than pulmonary vein isolation. The benefit was partly offset by more heart failure events and ...
Dr Jonathan Piccini discusses rhythm control in patients with atrial fibrillation and heart failure with preserved ejection fraction, the growing role of catheter ablation, and the evidence still needed to define its impact on cardiovascular outcomes.
Cardiovascular diseases (CVDs) are the leading cause of morbidity and mortality worldwide.1 High systolic blood pressure (SBP) remains one of the top risk factors for CVD burden globally.2 Despite being a modifiable risk factor, hypertension (HTN) remains largely undiagnosed and ...
The European Society of Cardiology (ESC) has published its first dedicated clinical practice guidelines on cardiac rehabilitation, calling for rehabilitation to be considered a core component of care across a broader range of cardiovascular conditions. Published in the European Heart ...
Prof. Thomas Thum discusses Phase II findings from the HF-REVERT study, what they suggest about patient selection for RNA-based therapies, and how these approaches could offer new ways to treat heart failure.
Prof. Maria Bäck discusses the first dedicated ESC Guidelines on cardiac rehabilitation, why personalization and multidisciplinary care are central to their recommendations, and the importance of increasing referral to rehabilitation programs.
Dr Jazmin Aguado-Sierra discusses how computational models and digital twins are helping researchers understand different heart failure phenotypes, and how artificial intelligence can accelerate analysis and support more personalized approaches.
Prof. Jens Cosedis Nielsen discusses the DANISH-CRT trial, why targeted electrical mapping did not improve outcomes, and the questions that remain around the future of cardiac resynchronization therapy.
Phase IIb LUMINARA data presented at ESC Congress 2026 suggest that AZD5462 may improve cardiac remodeling and hemodynamics across different heart failure phenotypes, with the lowest dose producing the strongest remodeling signal in HFrEF.
Prof. Jonathan Kalman discusses the rapid uptake of pulsed field ablation, its potential advantages over thermal ablation, and how the role of AF ablation may continue to expand.
Prof. Adriaan Voors discusses the evolving role of GLP-1 receptor agonists in heart failure, the importance of patient selection and monitoring, and how emerging evidence and new guidelines could influence clinical practice.
The first dedicated ESC Guidelines on the management of cardiovascular disease and chronic kidney disease recommend kidney function and urine albumin testing in all patients with cardiovascular disease, with an emphasis on identifying CKD early and initiating effective treatment without delay.
Eplontersen did not significantly reduce cardiovascular mortality and recurrent cardiovascular events compared with placebo in the overall CARDIO-TTRansform population, according to late-breaking results presented at ESC Congress 2026 in Munich, Germany.
New 2026 ESC Guidelines for the management of heart failure introduce major changes to the classification of heart failure and its treatment, with an increased focus on prevention, earlier intervention and timely referral of patients with advanced disease.
New heart failure guidelines, practice-changing Hot Line data, artificial intelligence and new evidence in atrial fibrillation and cardiac amyloidosis are among the highlights to look out for on the opening day of ESC Congress 2026.
Late-breaking clinical research will once again be a major focus at ESC Congress 2026, taking place in Munich, Germany, from August 28–31. This year, a record 59 trials have been selected for presentation across 12 Hot Line sessions, spanning new pharmacological approaches, diagnostic strategies, devices, imaging and digital technologies.
New clinical guidelines, late-breaking trials, artificial intelligence, and an increasing focus on cardiometabolic and precision medicine are set to shape discussions at ESC Congress 2026 in Munich.
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Sign up with an Email
Or use a .
Register now for FREE access
Already registered? Login below.
